LCAR-AIO / Legend Biotech 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
LCAR-AIO / Legend Biotech
NCT05318963: Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma

Recruiting
1
34
RoW
LCAR-AIO cells product
Qiu Lugui, Nanjing Legend Biotech Co.
B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory
06/24
06/26
NCT05292898: A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia

Active, not recruiting
1
20
RoW
LCAR-AIO Cells
Institute of Hematology & Blood Diseases Hospital, China, Nanjing Legend Biotech Co.
Acute Lymphocytic Leukemia
07/24
07/26
NCT06653556: A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus

Recruiting
1
34
RoW
LCAR-AIO T cells
Wuhan Union Hospital, China, Nanjing Legend Biotech Co., Beijing GoBroad Hospital
Systemic Lupus Erythematosus (SLE)
09/27
09/29
NCT06866080: A Study of LCAR-AIO in Subjects with Relapsed/Refractory Autoimmune Diseases

Recruiting
1
38
RoW
LCAR-AIO T cells
Nanjing Legend Biotech Co.
Relapsed/refractory Autoimmune Diseases
06/26
12/29
NCT06869278: A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases

Not yet recruiting
1
37
RoW
LCAR-AIO T cells
Wuhan Union Hospital, China, Nanjing Legend Biotech Co.
Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disease (NMOSD), Anti-Myelin Oligodendrocyte Glycoprotein-IgG Associated Disorders (MOGAD), Myasthenia Gravis
06/26
12/29

Download Options